TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Immunohistochemical expression of moesin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Tedizolid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of closure of biliary fistulas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gastro-oesophageal Reflux Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of N-Hydroxycitidine (NHC) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of NHC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half-life (t1/2) of NHC in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Ab/Ag results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence risk of microscopy-detectable P. vivax infections
Endpoint domain: Adverse events/effects
Primary endpoint: Disability related to upper limb damage
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptoms related to upper limb damage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants experiencing dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in participant confidence for kidney disease management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants diagnosed with SE, NCSE, and encephalitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of febril urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Children's autobiographical memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of the 24-hour period with intragastric pH>4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients diagnosed with chronic inflammatory demyelinating polyneuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of participants achieving immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time required for blood sugar to reach target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: loneliness scale for elderly
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Elder Self-Neglect Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in gastrointestinal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: POMS2-A short
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cortisol concentration in salivary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient reported outcome measures (PROMS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change during activity in 100mm Pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RP2D)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: FMS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent in Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 17-OHP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: A4 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total daily dose of Hydrocortisone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Tissue factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shift from normal to abnormal in ECG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CIN sensation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dual-task function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 24-hour urine sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient discharge time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Early postoperative Visual Analog Scale (VAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving of Game
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in peak flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Hemoglobin (Hb) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrence of atrial fibrillation or flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' engagement and adherence to the intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Missing rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diabetes Foot Care Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Foot Self Care Observation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetic Foot Care Self Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in substrate oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in inflammatory profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of dapiglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain due to the placement of the ultrasound-guided regional anesthesia block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumonia resolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Ktrans value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bournemouth Neck Pain Survey
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Energy cost of running
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes of renal doppler parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sustained Treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection and distinction of stroke types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessment of Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Colonization of L. crispatus strain in the vagina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonization of L. gasseri strain in the vagina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected visual acuity change (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central subfield thickness (CST) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of clinical worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of serious adverse events during clinical trial
Endpoint domain: Adverse events/effects
Primary endpoint: Participant's quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical activity progress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of follow-up survivorship visit
Endpoint domain: Mortality/survival
Primary endpoint: Completion of recommended screening tests
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum ALT concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of DAEs
Endpoint domain: Adverse events/effects
Primary endpoint: ICU outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiographic Progression-Free Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Intra-examination dispersion of liver stiffness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Sensitivity among hematuria patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity among hematuria patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Multidimensional Inventory Lifestyle Evaluation - Confinement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health Promoting Life-Style Profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change of cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: death in the ICU
Endpoint domain: Mortality/survival
Primary endpoint: need for renal replacement therapy during ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum creatinine value on the third day after randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Validity of the Hand-20 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Crow's Feet Wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in activity within the brain's 'default mode network'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration between triage and exit of emergency unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasted Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of respiratory disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change in the severity of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with Immunological rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in wart area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of any local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Port Wine Birthmark-Investigator Global Assessment (PWB-IGA) scale score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type 1 Diabetes and Life (T1DAL) Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported smoking prevalence 6-weeks after hospitalization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported use of FDA Approved Smoking Cessation Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of clinically significant abnormalities in laboratory values, vital signs, physical examination, and electrocardiogram (ECG) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADP-induced P2Y12 Receptor-mediated platelet aggregation of Tiprogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADP-induced P2Y12 Receptor-mediated platelet aggregation of Clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of Daily Living Activities Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cotinine verified 7 day point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of pressure sway range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of pressure velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of hemorrhagic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Physical Activity Participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in lower limb motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in motor output from surface EMG of lower limb muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete (R0) resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Global DNA methylation change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathy index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Freedom from Major Adverse Events (MAE) at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of study subjects with treatment success at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First time for requiring analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Injection-site Reactions (ISRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time-weighted Average (TWA) Daily Change From Baseline in Viral Load (log10 Copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Computed tomographic scan parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise capacity (Peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apheresis duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of CD14+ monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cmax of Caffeine and Paraxanthine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of Caffeine and Paraxanthine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-last of Caffeine and Paraxanthine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of Ovarian Reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of Participants Achieving Fibrosis Regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Occurrence of Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inventory of Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of suicide risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End tidal CO2 (PETCO2) value at arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of risky behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in patient quality of life (QOL) at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Genomic profiling results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (tlast) (AUC0-tlast) of M5049
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of opening length to field of view
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titer (GMT) ratio of SARS-CoV-2-specific neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion of SARS-CoV-2-specific neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency and severity of any Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Functional lung assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Holistic Well-Being Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feasibility of Weight Loss Intervention
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of Weight Loss Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient Health Questionnaire-4 (PHQ-4)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Recovering Quality of Life (ReQol-10)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: verbal working memory (CMS- digit span)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: non-verbal working memory (CMS - picture location)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Theory of mind (ToM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: The Timeline Follow Back (TLFB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Salivary cotinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache Management Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agility Test Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) rate at month 6
Endpoint domain: Mortality/survival
Primary endpoint: Immune landscape in chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of complete wound closure for target ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast) on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital staying length
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Modified Scale for HS Scar Severity (mSHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of decayed tooth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Perfusion in lower limb angiosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Oxygenation in lower limb angiosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of successful chromotubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Opt-in rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of ER visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with mental health issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alternative smoking product (ASP)-related knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk perceptions of ASPs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of ASPs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Alterations of LV mechanics responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in back-specific disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning